Overview
Compare with LogicMark, Inc., MYOMO, INC. or MILESTONE SCIENTIFIC INC., or pick any stock.
- TickerZJYL on Nasdaq2
- IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies2
- HeadquartersGeorge Town, Cayman Islands2
- Incorporated inCayman Islands4
- Business addressNo. 33 Lingxiang Road, Wujin District, Changzhou City, Jiangsu Province, F4 2131494
- Filer categoryNon-accelerated filer, Emerging growth company4
- Legal formcompany limited by shares2
- LEI254900PLEBMR3GBT52782
- StatusActive2
- LEI statusIssued and current2
- Registered addressC/O Vistra (Cayman) Limited, KY1-1205 George Town, Cayman Islands2
- Registered withGeneral Registry, OI-3592962
See how the biggest companies compare on our leaderboards
Co., Ltd., a wholly-owned subsidiary of Zhongjin HK and a limited liability company organized under the laws of the PRC, was incorporated.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Wheelchair brought in 78% of the revenue Jin Medical International Ltd. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Wheelchair | $16.3M | $14.9M | $16.2M |
| Other Products | $702.9K | $6.8M | $2.6M |
| Wheelchair Components | $2.8M | $1.9M | $1.9M |
Regions
Overseas Market brought in 79% of the revenue Jin Medical International Ltd. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Overseas Market | $17.1M | $14.9M | $16.3M |
| China Domestic Market | $2.7M | $8.6M | $4.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue71¢$14.6M
- Research and development8¢$1.6M
- Other costs15¢$3.1M
- Income tax1¢$214.6K
- Profit6¢$1.2M
Out of $20.7M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Capital spending100¢$6.6M
Out of $2.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.3
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Total revenue | $20.7M | $23.5M | $19.8M |
| Cost of revenue | -$14.4M | -$13.9M | -$12.9M |
| Business and sales related tax | -$198.3K | -$107.1K | -$180.1K |
| Total cost of revenue and related tax | -$14.6M | -$14.0M | -$13.0M |
| GROSS PROFIT | $6.0M | $9.5M | $6.8M |
| Selling expenses | -$1.3M | -$1.1M | -$453.3K |
| General and administrative expenses | -$2.5M | -$3.3M | -$1.9M |
| Research and development expenses | -$1.6M | -$1.5M | -$1.5M |
| Total operating expenses | -$5.4M | -$5.9M | -$3.9M |
| INCOME FROM OPERATIONS | $608.2K | $3.6M | $2.9M |
| Interest income, net | $789.1K | $466.5K | $182.7K |
| Foreign exchange gain (loss) | $23.1K | -$26.8K | -$50.4K |
| Other income, net | $175.5K | $105.2K | $222.4K |
| Total other income, net | $987.6K | $545.0K | $354.7K |
| INCOME BEFORE INCOME TAX PROVISION | $1.6M | $4.2M | $3.2M |
| PROVISION FOR INCOME TAXES | -$214.6K | -$763.9K | -$343.7K |
| NET INCOME | $1.4M | $3.4M | $2.9M |
| Less: net income (loss) attributable to non-controlling interest | $189.9K | -$256.1K | |
| NET INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD. | $1.2M | $3.7M | $2.9M |
| Foreign currency translation (loss) gain | -$361.2K | $841.5K | -$493.2K |
| Comprehensive income | $1.0M | $4.3M | $2.4M |
| Less: comprehensive income (loss) attributable to non-controlling interest | $196.5K | -$262.7K | |
| COMPREHENSIVE INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD. | $823.5K | $4.5M | $2.4M |
| Earnings per Ordinary Share - basic (in Dollars per share) | $0.01 | $0.02 | $0.02 |
| Earnings per Ordinary Share - diluted (in Dollars per share) | $0.01 | $0.02 | $0.02 |
| Weighted average shares - basic (in Shares) | 156.5M shares | 156.5M shares | 145.1M shares |
| Weighted average shares - diluted (in Shares) | 156.5M shares | 156.5M shares | 145.1M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash | $7.5M | $8.1M | ||
| Short-term investments | $22.2M | $18.6M | ||
| Accounts receivable, net | $5.8M | $5.9M | ||
| Inventories, net | $4.9M | $5.2M | ||
| Prepaid expenses and other current assets | $3.7M | $2.3M | ||
| TOTAL CURRENT ASSETS | $44.1M | $42.8M | ||
| Operating lease right-of-use assets | $85.2K | $256.1K | ||
| Property, plant and equipment, net | $7.9M | $1.5M | ||
| Land use right, net | $1.1M | $1.1M | ||
| Deferred tax assets, net | $141.8K | $121.3K | ||
| TOTAL NON-CURRENT ASSETS | $9.2M | $3.0M | ||
| TOTAL ASSETS | $53.4M | $45.8M | ||
| Short-term bank loans | $18.8M | $11.3M | ||
| Accounts payable | $3.3M | $3.0M | ||
| Accrued liabilities and other payables | $673.5K | $431.0K | ||
| Deferred revenue | $495.4K | $671.4K | ||
| Taxes payable | $302.3K | $1.1M | ||
| Operating lease liabilities, current | $72.6K | $185.2K | ||
| TOTAL CURRENT LIABILITIES | $23.8M | $17.2M | ||
| Operating lease liabilities, non-current | $96.2K | |||
| TOTAL NON-CURRENT LIABILITY | $96.2K | |||
| TOTAL LIABILITIES | $23.8M | $17.2M | ||
| Ordinary shares, $0.00005 par value, 1,000,000,000 shares authorized, 156,547,100 shares were issued and outstanding as of September 30, 2025 and 2024, respectively | $7.8K | $7.8K | ||
| Additional paid-in capital | $6.7M | $6.7M | ||
| Statutory reserves | $2.9M | $2.6M | ||
| Retained earnings | $20.9M | $20.0M | ||
| Accumulated other comprehensive loss | -$924.0K | -$556.2K | ||
| TOTAL SHAREHOLDERS EQUITY | $29.6M | $28.8M | ||
| Non-controlling interest | -$66.3K | -$262.7K | ||
| TOTAL EQUITY | $29.6M | $28.6M | $24.0M | $15.2M |
| TOTAL LIABILITIES AND EQUITY | $53.4M | $45.8M | ||
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized (in Shares) | 1.0B shares | 1.0B shares | ||
| Ordinary shares, shares issued (in Shares) | 156.5M shares | 155.9M shares | ||
| Ordinary shares, shares outstanding (in Shares) | 156.5M shares | 155.9M shares |
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash | $7.5M | $8.1M | ||
| Short-term investments | $22.2M | $18.6M | ||
| Accounts receivable, net | $5.8M | $5.9M | ||
| Inventories, net | $4.9M | $5.2M | ||
| Prepaid expenses and other current assets | $3.7M | $2.3M | ||
| TOTAL CURRENT ASSETS | $44.1M | $42.8M | ||
| Operating lease right-of-use assets | $85.2K | $256.1K | ||
| Property, plant and equipment, net | $7.9M | $1.5M | ||
| Land use right, net | $1.1M | $1.1M | ||
| Deferred tax assets, net | $141.8K | $121.3K | ||
| TOTAL NON-CURRENT ASSETS | $9.2M | $3.0M | ||
| TOTAL ASSETS | $53.4M | $45.8M | ||
| Short-term bank loans | $18.8M | $11.3M | ||
| Accounts payable | $3.3M | $3.0M | ||
| Accrued liabilities and other payables | $673.5K | $431.0K | ||
| Deferred revenue | $495.4K | $671.4K | ||
| Taxes payable | $302.3K | $1.1M | ||
| Operating lease liabilities, current | $72.6K | $185.2K | ||
| TOTAL CURRENT LIABILITIES | $23.8M | $17.2M | ||
| Operating lease liabilities, non-current | $96.2K | |||
| TOTAL NON-CURRENT LIABILITY | $96.2K | |||
| TOTAL LIABILITIES | $23.8M | $17.2M | ||
| Ordinary shares, $0.00005 par value, 1,000,000,000 shares authorized, 156,547,100 shares were issued and outstanding as of September 30, 2025 and 2024, respectively | $7.8K | $7.8K | ||
| Additional paid-in capital | $6.7M | $6.7M | ||
| Statutory reserves | $2.9M | $2.6M | ||
| Retained earnings | $20.9M | $20.0M | ||
| Accumulated other comprehensive loss | -$924.0K | -$556.2K | ||
| TOTAL SHAREHOLDERS EQUITY | $29.6M | $28.8M | ||
| Non-controlling interest | -$66.3K | -$262.7K | ||
| TOTAL EQUITY | $29.6M | $28.6M | $24.0M | $15.2M |
| TOTAL LIABILITIES AND EQUITY | $53.4M | $45.8M | ||
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized (in Shares) | 1.0B shares | 1.0B shares | ||
| Ordinary shares, shares issued (in Shares) | 156.5M shares | 155.9M shares | ||
| Ordinary shares, shares outstanding (in Shares) | 156.5M shares | 155.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net income | $1.4M | $3.4M | $2.9M |
| Amortization of operating lease right-of-use assets | $107.3K | $108.3K | |
| Depreciation and amortization | $243.4K | $237.8K | $225.9K |
| Loss (gain) on disposition of property and equipment | $36.7K | $2.6K | -$6.9K |
| Provision for (net recovery of) credit losses | $71.8K | -$47.5K | $120.3K |
| Accounts receivable written off | $37.0K | ||
| Deferred income tax (benefit) provision | -$22.1K | $36.3K | $89.6K |
| Short-term investments income | -$47.5K | -$45.0K | |
| Accounts receivable | $1.3M | -$2.4M | $348.7K |
| Accounts receivable - related parties | $989.9K | -$1.5M | -$724.8K |
| Inventories | $168.3K | $80.3K | $1.6M |
| Prepaid expenses and other current assets | -$770.9K | -$1.4M | -$716.4K |
| Accounts payable | $287.0K | -$499.6K | -$646.9K |
| Accrued liabilities and other payables | $245.9K | $97.2K | -$67.7K |
| Deferred revenue | -$163.6K | -$65.5K | -$102.9K |
| Deferred revenue - related parties | -$7.7K | $1.7K | $123.2K |
| Taxes payable | -$793.6K | $820.0K | $30.5K |
| Operating lease liabilities | -$144.1K | -$83.7K | |
| Net cash provided by (used in) operating activities | $2.9M | -$1.2M | $3.1M |
| Additions to property, plant and equipment | -$6.6M | -$144.9K | -$113.9K |
| Additions to land use right | -$979.3K | ||
| Proceeds from disposal of property and equipment | $444 | $348 | $10.1K |
| Prepayment for business acquisition | -$500.0K | ||
| Payments for short-term investments | -$9.7M | -$21.1M | -$12.1M |
| Redemption of short-term investments | $6.0M | $12.7M | $4.4M |
| Net cash used in investing activities | -$10.8M | -$9.5M | -$7.7M |
| Gross proceeds from initial public offerings | $8.0M | ||
| Direct costs disbursed from initial public offerings proceeds | -$1.2M | ||
| Proceeds from exercise of over-allotment option | $336.6K | ||
| Proceeds from sale of ordinary shares, net of issuance costs | $312.0K | ||
| Payment made for deferred offering costs | -$103.7K | ||
| Net proceeds from short-term bank loans | $19.0M | $12.4M | $5.7M |
| Repayment of short-term bank loans | -$11.4M | -$5.6M | -$1.4M |
| (Repayment of) proceeds from amount due to related parties | -$134.1K | $4.5M | -$4.5M |
| Net cash provided by financing activities | $7.4M | $11.7M | $6.9M |
| Effect of exchange rate changes on cash | -$139.6K | $273.6K | -$149.9K |
| Net (decrease) increase in cash | -$674.5K | $1.2M | $2.1M |
| Cash paid for income tax | $564.8K | $205.4K | $142.7K |
| Cash paid for interest | $411.1K | $239.4K | $5.3K |
| Deferred IPO cost offset with additional paid-in capital | $765.4K | ||
| Right of use assets obtained in exchange for operating lease liabilities | $358.0K | ||
| Reduction of right-of-use assets and operating lease obligations due to early termination of lease agreement | $57.7K |
No quarter-by-quarter statement was filed.
Corporate structure
Jin Medical International Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Jin Medical International Ltd.
- Erqi Wang Filed SCHEDULE 13D/A on Jin Medical International Ltd., latest Sep 25, 2026 (3 filings since Feb 14, 2024)
- NOVASTRALIST HORIZON LTD Filed SCHEDULE 13G on Jin Medical International Ltd., latest Aug 18, 2026
- Jin Medical International Ltd. George Town, Cayman Islands
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Jin Medical International Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $12.1M3 Sep 30, 2025 | $5.6M3 Sep 30, 2024 | +116.7% |
| Accumulated depreciation | $4.2M3 Sep 30, 2025 | $4.1M3 Sep 30, 2024 | +2.2% |
| Property and equipment, net | $7.9M3 Sep 30, 2025 | $1.5M3 Sep 30, 2024 | +440.7% |
| Operating-lease assets (leased space) | $85.2K3 Sep 30, 2025 | $256.1K3 Sep 30, 2024 | −66.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Marketable securities, current | $22.2M3 Sep 30, 2025 | $18.6M3 Sep 30, 2024 | +19.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated amortization | $111.8K3 Sep 30, 2025 | $86.8K3 Sep 30, 2024 | +28.8% |
| Finite-lived intangibles, net | $1.1M3 Sep 30, 2025 | $1.1M3 Sep 30, 2024 | −3.8% |
Inventory
Leadership
Who has led Jin Medical International Ltd., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerErqi Wang Apr 24, 2026 to now8
- Chief financial officerZiqiang Wang Apr 24, 2026 to now9
Board members and other officers (6)
- Board memberErqi Wang Apr 24, 2026 to now8
- Board memberYanru Guo Apr 24, 2026 to now10
- Board memberZiqiang Wang Apr 24, 2026 to now9
- Board memberJames Jiayuan Tong Apr 27, 2026 to now11
- Board memberOliver St Clair Franklin Jr. May 6, 2026 to now12
- Board memberNing Xue Jul 16, 2026 to now13
Timeline
Filings
107 filings to the SEC since October 2021: 4 annual reports, 6 insider forms, 4 large holders, 93 other. The latest 20:
- Sep 25, 2026SCHEDULE 13D/A EDGAR
- Sep 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 21, 2026SCHEDULE 13D EDGAR
- Aug 18, 2026SCHEDULE 13G EDGAR
- Aug 4, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 16, 20263 EDGAR
- Jul 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 30, 20266-K/A CURRENT REPORT EDGAR
- Jun 29, 20266-K CURRENT REPORT EDGAR
- Jun 4, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 6, 20263 EDGAR
- Apr 27, 20263 EDGAR
- Apr 24, 20263 EDGAR
- Apr 24, 20263 EDGAR
- Apr 24, 20263 EDGAR
- Apr 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Mar 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Feb 10, 202620-F ANNUAL REPORT EDGAR
The 107 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Erqi WangSCHEDULE 13D/A, 3 filings Feb 14, 2024 to Sep 25, 202614
- NOVASTRALIST HORIZON LTDSCHEDULE 13G, 1 filing Aug 18, 202615
SEC filer profile
How Jin Medical International Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARJin Medical International Ltd.1
- CIK0001837821
- Filer statusNon-accelerated filer an emerging growth company; not a shell company5
- Incorporated inCayman Islands5
- Fiscal year endsSeptember 301
- Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressNo. 33 Lingxiang Road, Wujin District, Changzhou City, Jiangsu Province, F4 2131491
- Phone(86)519896079721
- Shares outstanding156,547,100 shares as of Sep 30, 20255
- AuditorAudit Alliance LLP, Singapore PCAOB ID 3487; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceDec 28, 20201
- Filings114 in all: 6-K (43), CORRESP (14), UPLOAD (14), F-1/A (13), 3 (6), 20-F (3), 144 (2), EFFECT (2)1
All 24 form types
NT 20-F (2), 20-F/A (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), F-1 (1), F-3 (1), F-3/A (1), SC 13G (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (20-F) Feb 10, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary shares, par value $0.00005 per share | ZJYL | Nasdaq |
From the cover page of the 20-F filed Feb 10, 2026 (Section 12(b) of the Exchange Act).5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARErqi Wang, Chief executive officer
- 9
- 10SEC EDGARYanru Guo, Board member
- 11SEC EDGARJames Jiayuan Tong, Board member
- 12
- 13SEC EDGARNing Xue, Board member
- 14
- 15